Pharmena (WAR:PHR) Gross-Profit-to-Asset % : 0.24% (As of Sep. 2024)

View and export this data going back to 2008. Start your Free Trial

What is Pharmena Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Pharmena's annualized Gross Profit for the quarter that ended in Sep. 2024 was zł0.03 Mil. Pharmena's average Total Assets over the quarter that ended in Sep. 2024 was zł13.07 Mil. Therefore, Pharmena's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2024 was 0.24%.

Pharmena Gross-Profit-to-Asset % Historical Data

The historical data trend for Pharmena's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmena Gross-Profit-to-Asset % Chart

Pharmena Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

79.81

44.82

70.87

87.10

31.83

Pharmena Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															-0.19	92.55	0.17	2.24	0.24

Competitive Comparison of Pharmena's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Pharmena's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharmena's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmena's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Pharmena's Gross-Profit-to-Asset % falls into.

Save Embed

;

Save Embed

;

Pharmena Gross-Profit-to-Asset % Calculation

Pharmena's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	5.843	/	( (12.579	+	24.132)	/ 2 )
	=	5.843	/	18.3555
	=	31.83 %

Pharmena's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Sep. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Sep. 2024 ))	/ count )
	=	0.032	/	( (13.564	+	12.576)	/ 2 )
	=	0.032	/	13.07
	=	0.24 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Sep. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Pharmena Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Pharmena's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmena Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmena SA (WAR:PHR) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ulica Wolczanska 178, Lodz, POL, 90-530

Website

http://www.pharmena.pl

Pharmena SA produces cosmeceuticals and pharmaceuticals. The company's activity focuses on three areas such as research in the USA and Canada on the application of selected pyridinium salts in medicine in order to develop an anti-atherosclerosis drug on a global scale, Production and sales of innovative patented dermocosmetics and introduction into the market of an innovative dietary supplement for atherosclerosis prophylaxis. Its products include Menavitin, Dermena, Allerco and Thermi.